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OBJECTIVES We sought to assess the influence of long-term hydroxymethylglutaryl coenzyme A reductase
inhibition (statin) therapy on left ventricular (LV) remodeling after myocardial infarction
(MI) by use of serial cardiac magnetic resonance imaging (CMRI) studies.
BACKGROUND Statin therapy has been shown to reduce cardiac hypertrophy in vitro and in vivo, but the
influence on LV post-MI remodeling is largely unknown.
METHODS The CMRI measurements were taken four and 12 weeks after left coronary artery ligation in
a 7.05-tesla Biospec. The MI size, LV mass and volumes, cardiac output (CO), and ejection
fraction were determined. Rats were treated for 12 weeks with either placebo (P), cerivastatin
(C; 0.6 mg/kg body weight per day) as a dietary supplement, or cerivastatin plus the nitric
oxide synthase (NOS) inhibitor N-methyl-L-arginine methyl ester (L-NAME, 76 mg/100
ml) and hydralazine (8 mg/100 ml) in drinking water (CLH) to assess the contribution of
endogenous nitric oxide formation.
RESULTS Administration of cerivastatin attenuated hypertrophy after MI, and this effect was com-
pletely abolished by NOS inhibition (increase of LV mass from 4 to 12 weeks after MI: 235.3
 33.7 mg with P vs. 59.8  20.5 mg with C vs. 239.5  16.0 mg with CLH; p  0.05 vs.
P and CLH). Left ventricular dilation was not changed (increase of end-diastolic volume
from 4 to 12 weeks after MI: 108.7  28.8 with P vs. 126.6  20.5 with C vs. 173.7  25.1
with CLH; p  NS). The CO was higher in the cerivastatin group (12 weeks: 76.1  2.9
ml/min with P vs. 95.8  4.8 ml/min with C; p  0.05). The effects of cerivastatin were
abolished by NOS inhibition in the CLH group (CO at 12 weeks: 69.3  2.8 ml/min, p 
0.05 vs. C).
CONCLUSIONS Left ventricular remodeling was profoundly changed by statin treatment. Hypertrophy was
attenuated, and global function was improved. These positive effects were abolished by NOS
inhibition. (J Am Coll Cardiol 2002;40:1695–700) © 2002 by the American College of
Cardiology Foundation
Statin therapy has been shown to lower the incidence of
myocardial infarction (MI) through its positive effects on
atherosclerosis (1). Recently, it has been reported that
statins have effects beyond lipid lowering, and treatment
after MI may be beneficial not only for the secondary
prevention of repeat infarction (2–11). Proposed mecha-
nisms include antioxidant (2) and anti-inflammatory (3)
effects, upregulation of endogenous nitric oxide synthase
(eNOS) (4,5), reversal of endothelial dysfunction (6,7), and
induction of angiogenesis (8). In addition, statins attenuate
myocardial hypertrophy in vitro (9,10) and in vivo (11).
Furthermore, cerivastatin has been shown to improve blood
flow and reduce ischemic brain lesions in mice (12). Little is
known about the action of statins in left ventricular (LV)
remodeling post MI.
Therefore, the purpose of the present study was to
investigate the influence of statin therapy on cardiac remod-
eling in the rat model of coronary ligation and the role of
nitric oxide synthase (NOS) in its actions. The rat model of
MI has proved its usefulness in the introduction of
angiotensin-converting enzyme (ACE) inhibition therapy
after MI (13–15). It has an additional advantage for testing
the non–lipid-lowering effects of statin therapy, because
atherosclerosis is absent in this model. The remodeling
process was followed by serial cardiac magnetic resonance
imaging (CMRI) measurements, a noninvasive reference
standard for in vivo volumetry, which has previously been
validated in the rat MI model (16).
METHODS
Animals, experimental MI, and pharmacologic interven-
tions. Adult male Wistar rats weighing 269  3 g were
used when the study was started. Coronary artery ligation
was performed as described previously (17–19). In brief, rats
were anesthetized by isoflurane, intubated, and ventilated by
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a volume-constant rodent ventilator (UB 7025 rodent ven-
tilator, Hugo Sachs Elektronik, March, Germany), and a
left thoracotomy was performed. The heart was exteriorized
from the thorax, and the left coronary artery was ligated
using a 5.0 suture between the pulmonary artery outflow
tract and left atrium. The heart was then returned to its
normal position, and the thorax was closed. Animals were
housed in polyethylene cages in climatized rooms with a
12-h light/dark cycle and fed with standard laboratory food
and tap water. Rats were treated with either placebo,
cerivastatin (0.6 mg/kg body weight) starting on the seventh
postoperative day as a dietary supplement, or cerivastatin
plus N-methyl-L-arginine methyl ester (L-NAME) (76
mg/100 ml) and hydralazine (8 mg/100 ml) in drinking
water daily for 12 weeks. This dosage of hydralazine was
shown to counteract the increase of blood pressure induced
by L-NAME (20,21).
All procedures conformed to the guiding principles of the
American Physiological Society and were approved by the
institutional Animal Research Committee.
Cardiac magnetic resonance imaging. Non-invasive
CMRI was used to monitor the typical features of post-MI
remodeling consisting of hypertrophy and dilation of the
LV. In serial investigations, the influence of statin therapy
was assessed. Experiments were performed at 4 and 12
weeks after MI on a 7.05-tesla Biospec 70/21 (Bruker,
Germany) under inhalation anesthesia applied by a nose
cone (1.5% isoflurane supplemented with 0.5 l oxygen per
minute) using a rat-size whole-body coil. An electrocardio-
graphically triggered fast gradient echo sequence (22) was
used with the following parameters: flip angle 30° to 40°,
echo time 1.1 ms, repetition time (TR) 3.2 ms, and 12
frames per heart cycle. The total acquisition time for one
cine sequence was 40 to 50 s, depending on the heart rate,
and the acquisition window per frame was 6.2 ms (2 TR).
Data acquisition per slice was averaged four times to
increase the signal to noise ratio. For quantitative determi-
nation of the morphology and function, 18 to 22 contiguous
ventricular short-axis slices of 1-mm thickness were ac-
quired to cover the entire heart. With a field of view of 50
mm and an image matrix of 128  128, in-plane resolution
was 390 m.
Data analysis was performed using an operator-
interactive threshold technique by one trained observer.
Myocardial and ventricular slice volumes were determined
from end-diastolic and end-systolic images by multiplica-
tion of the compartment area and slice thickness (1 mm).
Total volumes were calculated as the sum of all slice
volumes. Left ventricular mass was calculated as LV end-
diastolic myocardial volume multiplied by the myocardial
specific gravity (1.05 g/cm3). The stroke volume (SV) and
ejection fraction (EF) were calculated using the end-
diastolic and end-systolic volumes (SV  EDV  ESV;
EF  SV/EDV). For cardiac output (CO), SV was multi-
plied by the heart rate. Myocardial infarct size was deter-
mined for every slice as the myocardial portion of the LV
with significant thinning and akinesia or dyskinesia during
systole (16). The relative MI size was calculated by taking
the sum of the endocardial and epicardial circumferences of
end-systolic frames occupied by the MI and dividing it by
the sum of the total epicardial and endocardial circumfer-
ences. This method has been previously validated by histo-
logic determination of infarct size (16). Absolute MI size, as
the area covered by MI, was obtained as follows: the average
length of the infarct-related section (sum of the endocardial
and epicardial circumferential lengths of the infarct area
divided by 2) of a single slice was multiplied by slice
thickness (1 mm). The infarct areas of all slices were totaled,
to calculate the area covered by scar tissue.
Polymerase chain reaction. Total ribonucleic acid (RNA)
was isolated from the surviving LV myocardium (septum)
using TRIzol reagent (Life Technologies), and the RNA
concentration was determined spectrophotometrically at
260 nm. After reverse transcription (SuperScript II, Life
Technologies), the alpha-actin iso-messenger RNAs
(mRNAs) were amplified by polymerase chain reaction
(PCR), as previously described (23), using digoxigenin-
labeled forward primers. After digestion with the restriction
enzyme SacI (Roche-Diagnostics GmbH, Mannheim, Ger-
many), the fragments of the PCR amplification product
were separated on 6% polyacrylamide gel (lengths: 202 base
pair [bp] for skeletal and 161 bp for cardiac alpha-actin).
The deoxyribonucleic acid fragments were transferred onto
a nylon membrane positively charged (Roche) and exposed
to film suitable for detection of chemiluminescence (Kodak
BioMax Light, Eastman Kodak, Rochester, New York).
The resultant bands on the autoradiograms were then
quantified with NIH Image (version 1.61, National Insti-
tute of Health, Bethesda, Maryland), and the results were
expressed as the ratio of skeletal alpha-actin mRNA to
cardiac alpha-actin mRNA.
Data analysis. The results are expressed as the mean value
 SEM. Statistical comparisons among various groups over
time were evaluated by analysis of variance, followed by the
Duncan test to isolate the significance of differences be-
tween individual mean values. A p value 0.05 was con-
sidered to indicate statistical significance.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CMRI  cardiac magnetic resonance imaging
CO  cardiac output
EF  ejection fraction
eNOS  endogenous nitric oxide synthase
L-NAME  N-methyl-L-arginine methyl ester
LV  left ventricle or ventricular
MI  myocardial infarction
SV  stroke volume
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RESULTS
Typical examples of CMRIs are shown in Figure 1. Short-
axis slices were used for quantification. Infarcts were similar
in all groups and, on average, 30% (Table 1).
As shown in Figure 2, the LV mass increased after MI in
the placebo group, associated with a marked increase in
skeletal actin expression (Fig. 3). Statin treatment almost
completely inhibited the increase in LV mass (Fig. 2) and
significantly reduced skeletal actin expression (Fig. 3). Co-
treatment with the NOS inhibitor L-NAME and hydralazine
reversed the effect of cerivastatin on LV mass (Fig. 2) and
significantly reduced skeletal actin expression (Fig. 3).
Dilation of the LV after MI was not prevented by
cerivastatin (Fig. 4A), and LVEF was not significantly
improved (Fig. 4B). Cardiac output was higher in the
groups treated with cerivastatin (Fig 5A); this was due to a
higher heart rate (Table 1) and larger SVs (12 weeks after
MI: 240.7  11.0 l with placebo vs. 273.7  8.9 l with
cerivastatin; p  NS).
Wall motion analysis revealed a decline of systolic wall
thickening of the remote region during the remodeling
process. This was found to be significant in all MI groups,
with exception of rats treated with cerivastatin (Fig. 5B).
Therefore, treatment with cerivastatin was able to preserve
regional function of the remote region to a certain degree.
Again, this effect was reversed by co-treatment with
L-NAME and hydralazine (Fig. 5B).
In the rats given placebo, the area covered by scar tissue
increased by 7  5.3 mm2, and in rats treated with
cerivastatin, by 5.1 5.9 mm2. In the group co-treated with
L-NAME, the increase in infarct size was significantly
higher (33.8  5.1 mm2; p  0.05 vs. placebo and
cerivastatin).
DISCUSSION
The major novel result of this study is a substantial
reduction of post-MI LV hypertrophy by cerivastatin.
Co-treatment with a NOS inhibitor fully counteracted the
effects of the statin.
Figure 1. Typical mid-ventricular diastolic and systolic short-axis slices 12
weeks after myocardial infarction. Heart from a rat treated with cerivastatin
(myocardial infarction size 40%).





Cerivastatin  L-NAME Group
(n  11)
4 Weeks 12 Weeks 4 Weeks 12 Weeks 4 Weeks 12 Weeks
MI size (%) 32  3 30  3 32  1 31  2 32  3 35  2
Body weight (g) 286.6  6.1 305.2  5* 212.6  6.2† 257  4.7*† 205.4  6.1† 246.5  6.9*†
LV mass (mg) 500.4  14.8 735.7  38.4* 592.9  15.6† 652.7  16.3*† 500.6  18.4‡ 740.1  17.7*‡
Heart rate (beats/min) 310  10 318  11 372  8† 360  9† 327  5‡ 317  13‡
EDV (l) 591.3  40.8 700.1  67.6* 549  21.3 675.7  34.6* 518.3  17.2† 692.0  34.7*
SWT (%) 17.3  4.9 11.1  5.3† 21.1  5.8‡
*p  0.05 vs. 4 weeks. †p  0.05 vs. placebo group. ‡p  0.05 vs. cerivastatin  L-NAME group. Data are presented as the mean value  SEM.
EDV end-diastolic volume; L-NAME N-methyl-L-arginine methyl ester; LV left ventricular; MImyocardial infarction; SWT change in systolic wall thickening
from 4 to 12 weeks.
Figure 2. Hypertrophy after myocardial infarction (MI). (A) Increase in
left ventricular (LV) mass (mg) from 4 to 12 weeks after MI. (B) Change
in wall thickness (mm) in the remote region. Data are presented as the
mean value  SEM. *p  0.05 vs. Sham Plac, Sham Cer, and MI Cer.
Cer  cerivastatin; Plac  placebo.
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Post-MI remodeling. In the placebo group, features of LV
remodeling, such as an increase in LV mass and progressive
dilation of the LV, were detected by serial measurements,
which are feasible due to the noninvasive character of
CMRI. The distinct effects of the treatment found in this
study are partly due to the possibility of imaging the same
animal a second time and hence monitoring the induced
change.
Changes in LV morphology led to impaired function, as
characterized by a reduced EF (Fig. 4B) and impaired
systolic wall thickening (Fig. 5B). These findings are in
accordance with data obtained by invasive diagnostic pro-
cedures (17–19) and previous CMRI studies in rats after MI
(24,25). Furthermore, these results resemble observations in
patients developing heart failure after MI due to chronic LV
remodeling (26).
Impact of statin treatment. In this study, evidence for
prevention of post-MI hypertrophy by statin is provided by
prevention of an increase in LV mass, wall thickness, and
expression of skeletal actin. Activation of the renin-
angiotensin system may contribute to hypertrophy after MI
(27). Although in the early post-MI phase, hypertrophy
may be necessary to reduce regional wall stress and maintain
CO and peripheral perfusion, pathologic hypertrophy pro-
motes the progression of the infarct-related ventricle into
failure (28–30). Statins have been shown to reduce angio-
tensin II-induced hypertrophy in vitro, mainly by attenua-
tion of p21 ras activity (10) and antioxidant properties (2).
In a recent study, cerivastatin prevented the LV expression
of fetal genes such as beta-myosin heavy chain, and it
reduced collagen I gene expression in rats after MI (31). In
transgene cardiomyopathic rabbits, simvastatin induced the
regression of hypertrophy and fibrosis (32). In the present
study, the attenuated LV remodeling resulted in a higher
CO (Fig. 5A) and wall thickening of the remote region
(Fig. 5B). However, LV dilation and a decline in EF were
not reversed by statin treatment (Fig. 4).
Role of nitric oxide (NO). Increased expression and ac-
tivity of eNOS during statin treatment have been reported
in several experimental settings, both in vitro and in vivo
Figure 3. Representative autoradiograph and statistical analysis showing the effects of long-term therapy with cerivastatin after myocardial infarction (MI)
on left ventricular (LV) gene expression (n 5 or 6 per group) of the iso-messenger ribonucleic acids for skeletal and cardiac alpha-actin. Two representative
lanes are shown for each group, each from a separate rat. *p  0.05 vs. Sham Plac. †p  0.05 vs. MI Plac. Cer  cerivastatin; Plac  placebo.
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(4,5). Left ventricular eNOS expression was markedly
increased in rats after MI, suggesting that the beneficial
effects of cerivastatin may be mediated by an improved
NO/O2
 balance (31). The present study supports this
concept, as inhibition of NOS by L-NAME almost com-
pletely abolished the effects of statin treatment.
Infarct expansion. Despite an identical relative infarct size
at 4 weeks after MI (31.5  2.7% with placebo vs. 31.9 
1.4% with cerivastatin vs. 31.9 2.8% with cerivastatin plus
L-NAME), only the last group’s relative infarct size further
increased to 34.5  2.4% at 12 weeks. We therefore
calculated infarct size as an absolute measure by multiplying
the circumferential length of the noncontractive zone by
slice thickness and found a significant increase in the
noncontractive area of the LV only in rats treated with
L-NAME. It is therefore likely that inhibition of NOS
aggravates late scar remodeling. One could speculate that
the shift in the NO/O2
 balance with consecutively en-
hanced generation of reactive oxygen species (31) might lead
to infarct expansion. Higher distention forces on the scar are
not likely to be the cause of increased infarct expansion,
because co-administration of hydralazine minimized pre-
load and after-load (33).
Clinical implications. Many patients who have had an MI
will be treated with statins for secondary prevention of
coronary heart disease. This study suggests that a pleiotropic
effect of statins also appear to retard LV hypertrophy in the
rat model of chronic MI. Statin therapy may be an addi-
tional option for this group of patients, complementary to
ACE inhibitor medication, which can prevent LV dilation,
heart failure, and death (34).
Study limitations. This animal study may not directly
represent the patient’s situation. However, the rat model of
heart failure after MI closely mimics the clinical syndrome
of heart failure in patients and has proven value for research
into pharmacologic intervention. For instance, the beneficial
effects of ACE inhibitors after MI were first demonstrated
in the rat model (13) and provided the basis for large studies
of patients (34). Another concern may be that cerivastatin is
not representative of all statins. However, the reduction of
LV hypertrophy in several models by other statins (2,32)
Figure 4. Dilation after myocardial infarction (MI). (A) Increase in
end-diastolic volume (l) from 4 to 12 weeks after MI. (B) Ejection
fraction (%) 12 weeks after MI. Data are presented as the mean value 
SEM. *p  0.05 vs. Sham Plac and Sham Cer. †p  0.05 vs. MI Cer.
Cer  cerivastatin; Plac  placebo.
Figure 5. Left ventricular function. (A) Cardiac output (ml/min) 12 weeks
after myocardial infarction (MI). *p  0.05 vs. MI Plac and MI Cer plus
L-NAME. (B) Systolic wall thickening (%) in the remote region 12 weeks
after MI. Data are presented as the mean value  SEM. *p  0.05 vs.
Sham Plac.
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supports the concept of a class effect attributable to all
statins, rather than a specific effect of cerivastatin.
Conclusions. Serial CMRI facilitated the analysis of statin
effects after MI. Left ventricular dilation was unchanged,
but cerivastatin drastically reduced LV hypertrophy. The
effects are likely to be caused by increased NOS, because
inhibition of NOS completely abolished the effects of
hydroxymethylglutaryl coenzyme A reductase inhibition.
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